Traditional Chinese medicine composition for treating lung cancer as well as preparation method and application of traditional Chinese medicine composition

Through a composition containing a variety of traditional Chinese medicine ingredients, it inhibits the proliferation and invasion and metastasis of lung cancer cells, solves the problems of low chemotherapy sensitivity and great toxic side effects in the treatment of advanced non-small cell lung cancer, and achieves the effect of improving symptoms and prolonging survival .

CN118976085APending Publication Date: 2024-11-19HUNAN ACAD OF CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411390203.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-03-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing methods for treating advanced non-small cell lung cancer, such as radiotherapy and chemotherapy, have low sensitivity and great toxic side effects, and patients often have distant lesions metastases when diagnosed, losing the opportunity for surgical operations. Traditional Chinese medicine has the characteristics of regulating the overall function of the host, but The application in lung cancer treatment has not been fully utilized.

Method used

Provided a traditional Chinese medicine composition, including Codonopsis pilosula, Astragalus, Ganoderma lucidum, Cat's claw, Houttuynia cordata, Ligustrum, Curcuma zedo, Fritillaria zedo, Fritillaria stinky peony and Snaketone sirloin, by inhibiting A549 cells PI3K/ The p-Akt pathway downregulates VEGFR and MMP9 expression, inhibits the proliferation and invasion and metastasis of lung cancer cells, reduces chemotherapy toxicity and side effects, and improves chemotherapy resistance.

Benefits of technology

This traditional Chinese medicine composition effectively inhibits the proliferation and invasion and metastasis of lung cancer cells, reduces toxic and side effects of chemotherapy, improves the clinical symptoms of patients, improves the quality of life, and prolongs survival. It has no obvious adverse reactions, and has the effect of preventing and treating recurrence and metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976085A_ABST
    Figure CN118976085A_ABST
Patent Text Reader

Abstract

The invention provides application of granules of a traditional Chinese medicine composition in preparation of a medicine for inhibiting a PI3K / p-Akt pathway, and the traditional Chinese medicine composition comprises the following raw material components in parts by weight: 5-30 parts of codonopsis pilosula; 7.5 to 45 parts of radix astragali seu hedysari; 5 to 30 parts of lucid ganoderma; 7.5 to 45 parts of radix ranunculi ternati; 7.5 parts to 45 parts of herba houttuyniae; 5-30 parts of glossy privet fruit; 5 to 30 parts of curcuma zedoary; 5 to 30 parts of thunberg fritillary bulb; 7.5 to 45 parts of sculellaria barbata; 7.5 to 45 parts of clerodendrum bungei; and 7.5 to 45 parts of spreading hedyotis herb.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating lung cancer, and a preparation method and use thereof. Background Art

[0002] Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. The first treatment for early non-small cell lung cancer is surgery. Due to the lack of characteristic symptoms, about 65%-80% of NSCLC patients are already in the middle and late stages when diagnosed, with distant lesions metastasized, and thus lose the opportunity for surgery or cannot tolerate surgery. Even if surgery is performed, serious complications are likely to occur after surgery. Therefore, radiotherapy / chemotherapy combined treatment is the first treatment mode for advanced non-small cell lung cancer, but its sensitivity is low and its toxic side effects are large. Traditional Chinese medicine has the function of regulating the overall function of the host in preventing and treating tumors, and has the functions of eliminating evil and strengthening the body, increasing efficacy and reducing toxicity. Its characteristics lie in the overall regulation of multiple targets and levels. Based on real-world clinical big data research, a total of 7435 independent syndrome differentiation medical records of 390 NSCLC patients were retrospectively investigated and analyzed, and medical records related to NSCLC were screened out. Data mining techniques such as frequency statistics, cluster analysis, principal component analysis, and association analysis were used to explore the laws of modern TCM syndrome differentiation and treatment of NSCLC. It was proposed that the main pathogenesis of lung cancer is "deficiency of both Qi and Yin, phlegm, blood stasis and toxin accumulation", and the treatment should be based on "invigorating Qi and nourishing Yin, resolving phlegm and blood stasis, clearing away heat and detoxifying, and attacking toxins and dispersing accumulation" throughout the entire treatment process. Summary of the invention

[0003] The present application provides a Chinese medicine composition for treating lung cancer, and a preparation method and use thereof. The Chinese medicine composition can effectively inhibit the proliferation of lung cancer cells and promote apoptosis thereof, inhibit the EMT process by inhibiting the PI3K / p-Akt pathway of A549 cells, downregulate the expression of angiogenesis receptor VEGFR and matrix metalloproteinase MMP9, thereby playing an anti-lung cancer invasion and metastasis effect, reducing the toxic and side effects caused by radiotherapy and chemotherapy, playing a synergistic sensitization effect, improving chemotherapy drug resistance, improving the clinical symptoms of tumor patients, regulating functions, improving the quality of life, without obvious adverse reactions, preventing and treating the recurrence and metastasis of lung cancer to a certain extent, and maximally prolonging the survival period, thereby improving the clinical benefit rate.

[0004] In a first aspect, the present application provides a Chinese medicine composition, comprising the following raw material components by weight:

[0005] Codonopsis pilosula, 5 to 30 parts; Astragalus membranaceus, 7.5 to 45 parts; Ganoderma lucidum, 5 to 30 parts; Cat's claw, 7.5 to 45 parts; Houttuynia cordata, 7.5 to 45 parts; Ligustrum lucidum, 5 to 30 parts; Curcuma zedoaria, 5 to 30 parts; Fritillaria thunbergii, 5 to 30 parts; Scutellaria barbata, 7.5 to 45 parts; Clematis chinensis, 7.5 to 45 parts; Oldenlandia diffusa, 7.5 to 45 parts.

[0006] In the technical solution of the present application, by rationally selecting the active ingredients of traditional Chinese medicine and their contents, various active ingredients of traditional Chinese medicine work synergistically, so that the traditional Chinese medicine composition can effectively inhibit the proliferation, invasion and metastasis of lung cancer tumor cells, and can also promote their apoptosis. In addition, the traditional Chinese medicine composition has the effects of improving the clinical symptoms of patients, improving the quality of life of patients, regulating functions, improving physical fitness, and prolonging the survival of patients.

[0007] In some embodiments of the present application, the following raw material components are also included: Codonopsis pilosula, 5 to 25 parts; Astragalus membranaceus, 7.5 to 40 parts; Ganoderma lucidum, 5 to 25 parts; Cat's claw, 7.5 to 35 parts; Houttuynia cordata, 7.5 to 40 parts; Ligustrum lucidum, 5 to 20 parts; Curcuma zedoaria, 5 to 20 parts; Fritillaria thunbergii, 5 to 26 parts; Scutellaria barbata, 7.5 to 38 parts; Paeonia suffruticosa, 7.5 to 40 parts; Hedyotis diffusa, 7.5 to 37 parts.

[0008] In a second aspect, the present application further provides a method for preparing the Chinese medicine composition as described in any one of the above items, comprising the following steps: S10: weighing the raw material components of the Chinese medicine composition according to a proportion, extracting the raw material components, and filtering to obtain a filtrate;

[0009] S20: concentrating the filtrate to obtain a thick paste;

[0010] S30: drying the thick paste to obtain a dry paste;

[0011] S40: Grind the dry paste to obtain a Chinese medicine composition.

[0012] In the technical scheme of the present application, by reasonably selecting the raw material components and their contents and adopting an appropriate preparation process, the advantages of rapid absorption and quick action are retained on the basis of retaining the therapeutic effect of the decoction. Compared with the decoction, it has the advantages of convenient production, high yield, small dosage, good taste, not easy to mold, easy to carry, store and transport, not easy to deteriorate for a long time, and better stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0014] Figure 1A and B are schematic diagrams of the tumor sizes of nude mice in the model group, chemotherapy group, and Chinese medicine preparation + chemotherapy group in some embodiments of the present application;

[0015] Figure 1 Middle C is a pathological section diagram of nude mice in some embodiments of the present application;

[0016] Figure 1 D is a curve chart showing the changes in nude mouse body weight and tumor volume over time in some embodiments of the present application;

[0017] Figure 1 Middle E is an expression diagram of α-SMA examined by immunohistochemistry in some embodiments of the present application;

[0018] Figure 2 A, B, C and D are flow cytometry cell apoptosis images of the control group, low-dose, medium-dose and high-dose Chinese medicine groups in this application, respectively;

[0019] Figure 2 Middle E and F are the protein immunoblot images of PI3K / p-Akt, VEGFR, MMP9, key factors of epithelial-mesenchymal transition (EMT) in lung cancer A549 cells in the blank control group, low-, medium- and high-dose groups of traditional Chinese medicine in this application;

[0020] Figure 3 A schematic diagram showing the principle of the granules of the present invention inhibiting the PI3K / p-Akt pathway.

[0021] The above drawings have shown clear embodiments of the present application, which will be described in more detail later. These drawings and text descriptions are not intended to limit the scope of the present application in any way, but to illustrate the concept of the present application to those skilled in the art by referring to specific embodiments. DETAILED DESCRIPTION

[0022] In order to make the purpose, technical solutions and advantages of this application clearer, the technical solutions in the embodiments of this application will be clearly and completely described below in combination with the embodiments of this application. Obviously, the described embodiments are part of the embodiments of this application, not all of them. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0023] The present application provides a Chinese medicine composition, which includes the following raw material components by weight: Codonopsis pilosula, 5 to 30 parts; Astragalus membranaceus, 7.5 to 45 parts; Ganoderma lucidum, 5 to 30 parts; Cat's claw, 7.5 to 45 parts; Houttuynia cordata, 7.5 to 45 parts; Ligustrum lucidum, 5 to 30 parts; Curcuma zedoaria, 5 to 30 parts; Fritillaria thunbergii, 5 to 30 parts; Scutellaria barbata, 7.5 to 45 parts; Paeonia suffruticosa, 7.5 to 45 parts; Hedyotis diffusa, 7.5 to 45 parts.

[0024] In the technical scheme of the present application, by reasonably selecting the active ingredients of traditional Chinese medicine and their contents, the synergistic effect of various active ingredients of traditional Chinese medicine makes the traditional Chinese medicine composition able to effectively inhibit the proliferation, invasion and metastasis of lung cancer tumor cells, and can also promote their apoptosis, reduce the toxic and side effects caused by chemotherapy, etc., play a synergistic sensitization effect, improve chemotherapy drug resistance, improve the clinical symptoms of tumor patients, regulate functions, improve the quality of life, have no obvious adverse reactions, prevent and treat the recurrence and metastasis of lung cancer to a certain extent, and maximize the survival period, thereby improving the clinical benefit rate.

[0025] Codonopsis pilosula is sweet and neutral in nature. It has the effects of replenishing qi, quenching thirst, strengthening the spleen and lungs, and nourishing blood and producing body fluid. It is used for spleen and lung qi deficiency, lack of appetite and fatigue, cough and asthma, qi and blood deficiency, sallow complexion, palpitations and shortness of breath, thirst due to loss of body fluid, and internal heat.

[0026] Astragalus: It has the effects of replenishing Qi and strengthening the exterior, expelling toxins and pus, promoting diuresis and promoting tissue regeneration.

[0027] Ganoderma lucidum is the dried fruiting body of Ganoderma lucidum (Leyss.ex Fr.) Karst. or Ganoderma sinense Zhao, Xu et Zhang. It has the effects of replenishing qi and calming the mind, relieving cough and relieving asthma. It is used to treat restlessness, insomnia, palpitations, cough, asthma, sputum and asthenia.

[0028] Cat's claw is the dried root of Ranunculus ternatus Thunb., a plant of the Ranunculaceae family. It has the effects of resolving phlegm and dispersing nodules, detoxifying and reducing swelling. It is often used to treat scrofula, phlegm nodules, carbuncle swelling and poison, and snake and insect bites.

[0029] Houttuynia cordata is pungent in taste and cold in nature. It belongs to the lung meridian. It has the effects of clearing away heat and detoxifying, reducing swelling and curing sores, promoting diuresis and removing dampness, clearing heat and stopping diarrhea, and strengthening the stomach and digestion. It is used to treat lung abscesses, sores and swelling, hemorrhoids, bloody stools, and spleen and stomach heat caused by real heat, heat toxins, dampness, and rapid heat.

[0030] Fructus Ligustri Lucidi is flat in nature, sweet and bitter in taste, and enters the liver and kidney meridians. It has the effects of nourishing yin and longevity, tonifying the liver and kidney, clearing away heat and improving eyesight, and blackening hair. It is often used to treat symptoms such as dizziness, tinnitus, blurred vision, soreness of waist and knees, internal heat, and premature graying of hair.

[0031] Curcuma zedoaria is used to treat symptoms such as stagnation of qi and blood, distension and pain in the heart and abdomen, masses, accumulation, indigestion, blood stasis and amenorrhea in women, and pain caused by falls.

[0032] Fritillaria thunbergii has the effects of clearing away heat and resolving phlegm, dispersing stagnation and detoxifying. It is used to treat wind-heat cough, lung abscess, throat paralysis, scrofula, sores, swelling and poison.

[0033] Scutellaria barbata is cold in nature and sour in taste. The whole plant contains a variety of vitamins, trace elements, amino acids and other ingredients. It has the effects of clearing away heat and detoxification, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and anti-cancer.

[0034] The stems, leaves and roots of stinking peony are used as medicine. Stems and leaves: pungent, slightly bitter, neutral; roots: pungent, bitter, slightly warm. Stems and leaves: have the effects of detoxification, swelling, rheumatism and lowering blood pressure. Roots: have the effects of promoting qi and strengthening the spleen, dispelling wind and dampness, detoxification, swelling and lowering blood pressure.

[0035] The finished product of Hedyotis diffusa is bitter and light in taste and cold in nature. It has the effects of clearing away heat and detoxifying, relieving pain and dispersing stagnation, and promoting diuresis and removing dampness. It is especially used to treat various types of inflammation.

[0036] In some embodiments of the present application, the following raw material components are also included: Codonopsis pilosula, 5 to 25 parts; Astragalus membranaceus, 7.5 to 40 parts; Ganoderma lucidum, 5 to 25 parts; Cat's claw, 7.5 to 35 parts; Houttuynia cordata, 7.5 to 40 parts; Ligustrum lucidum, 5 to 20 parts; Curcuma zedoaria, 5 to 20 parts; Fritillaria thunbergii, 5 to 26 parts; Scutellaria barbata, 7.5 to 38 parts; Paeonia suffruticosa, 7.5 to 40 parts; Hedyotis diffusa, 7.5 to 37 parts.

[0037] The present application also provides a method for preparing the Chinese medicine composition as in any of the above embodiments, comprising the following steps:

[0038] S10: weighing raw material components of the Chinese medicine composition according to proportion, extracting the raw material components, and filtering to obtain a filtrate; S20: concentrating the filtrate to obtain a thick paste;

[0039] S30: drying the thick paste to obtain a dry paste;

[0040] S40: Grind the dry paste to obtain a Chinese medicine composition.

[0041] In the technical solution of the present application, a Chinese medicine composition with a high yield can be obtained by reasonably selecting raw material components and their contents and using an appropriate preparation process.

[0042] In some embodiments of the present application, step S10 includes the following steps: S11: weighing the raw material components of the traditional Chinese medicine composition according to the proportion, adding water to the raw material components for two decoctions, and obtaining a first decoction and a second decoction, respectively; S12: filtering the first decoction and the second decoction, respectively, using a filter screen of about 200 mesh, and then combining the filtered medicinal liquids to obtain a filtrate; wherein the ratio of the amount of water added for each decoction to the total weight of the raw material components is 10 to 12:1, and the time for each decoction is 60 min to 90 min.

[0043] In some of the above embodiments, adding water to the raw material components for decoction can not only save costs, but also reduce pollution to the environment. The two decoctions can effectively extract the active ingredients of the raw material components, and based on economic, time-saving and energy-saving considerations, the ratio of the amount of water added to the total weight of the raw material components for each decoction is 10 to 12:1, and the time for each decoction is 60 minutes to 90 minutes. The number of decoctions, the amount of water added and the decoction time within the above range can help improve the yield of the dry paste.

[0044] In some embodiments of the present application, step S20 includes the following steps: S21: concentrating the above-mentioned filtrate to a thick paste with a relative density of 1.20 to 1.25 at 60°C, wherein the concentration temperature is 60°C to 65°C, and the concentration vacuum degree is -0.08MPa to -0.06MPa.

[0045] In some of the above embodiments, the concentration conditions are within the above range, which can help extract the active ingredients and improve the quality. In some embodiments of the present application, step S30 includes the following steps: S31: drying the thick paste at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste.

[0046] In some of the above embodiments, the temperature and vacuum degree of vacuum drying are within the above ranges, which is beneficial to improving the quality of the dry paste. In a third aspect, the present application provides a Chinese medicine preparation, including the Chinese medicine composition in any of the above embodiments, and pharmaceutically acceptable excipients.

[0047] In some embodiments of the present application, the auxiliary material is selected from diluents, sweeteners and wetting agents. The diluent can help reduce the hygroscopicity of the Chinese medicine composition and improve the fluidity and compressibility of the Chinese medicine composition. The sweetener can help improve the taste of the Chinese medicine preparation. The wetting agent can help improve the yield and qualified rate of the Chinese medicine preparation.

[0048] In some optional embodiments of the present application, the mass ratio of the Chinese medicine composition to the diluent is 1:(1.4-1.8). The diluent within the above range can further reduce the hygroscopicity of the Chinese medicine composition and improve the fluidity and compressibility of the Chinese medicine composition. Further, the diluent can be selected from dextrin, which can help the Chinese medicine preparation not to clog the screen during the preparation process and has good solubility. In addition, dextrin is cheap and has good moisture resistance.

[0049] In some optional embodiments of the present application, the mass ratio of the Chinese medicine composition to the sweetener is 1:(0.003-0.007). The sweetener within the above range can further enhance the taste of the Chinese medicine preparation.

[0050] Furthermore, the sweetener is selected from stevioside, which is a mixture mainly composed of stevioside. The sweetness of stevioside is about 300 times that of sucrose. As a non-caloric sweetener, stevioside has the effects of lowering blood pressure, promoting metabolism, and treating hyperacidity.

[0051] In some optional embodiments of the present application, the amount of the wetting agent is 30 mL to 40 mL per 100 g of the Chinese medicine composition. The wetting agent is designed within the above range, which can help improve the yield and qualified rate of the Chinese medicine preparation.

[0052] Furthermore, the wetting agent is selected from ethanol, and the mass fraction of the ethanol is greater than or equal to 90%, which can further improve the yield of the traditional Chinese medicine preparation and also improve the quality of the traditional Chinese medicine preparation.

[0053] In some embodiments of the present application, the Chinese medicine preparation is a granule, which can maintain the advantages of rapid action of the decoction, and also has the characteristics of small volume, convenient administration, storage and transportation, stable properties, and controllable quality, and is therefore suitable for industrial production. In a fourth aspect, the present application also provides the use of the Chinese medicine composition described in the above embodiments or the Chinese medicine preparation described in any of the above embodiments in the preparation of a drug for treating lung cancer.

[0054] The preparation and use of the Chinese medicine composition and Chinese medicine preparation of the present application are described in detail below.

[0055] Example 1

[0056] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0057] Weigh a total of 70g of raw material components: 5g of Codonopsis pilosula, 7.5g of Astragalus, 5g of Ligustrum lucidum, 5g of Ganoderma lucidum, 5g of Curcuma zedoaria, 7.5g of Herba Lycopodii, 5g of Fritillariae Scutellariae, 7.5g of Scutellaria barbata, 7.5g of Stinking Paeonia lactiflora, 7.5g of Herba Hedyotis diffusae, add water and boil three times, add 12 times the amount of water for the first time and boil for 2.0h to obtain the first decoction; add 10 times the amount of water for the second time and boil for 1.5h to obtain the second decoction; add 10 times the amount of water for the third time and boil for 1.0h to obtain the third decoction;

[0058] Filtering the first decoction, the second decoction and the third decoction respectively through a 200-mesh filter to obtain a first filtrate, a second filtrate and a third filtrate respectively;

[0059] The first filtrate, the second filtrate and the third filtrate are respectively concentrated to a first thick paste, a second thick paste and a third thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature is 55° C. to 60° C., the concentration vacuum degree is -0.08 MPa to -0.06 MPa, and the concentration time is 7 hours;

[0060] Drying the first thick paste, the second thick paste and the third thick paste at a temperature of 60° C. to 70° C. and a vacuum degree of -0.08 MPa to -0.06 MPa to obtain a first dry paste, a second dry paste and a third dry paste;

[0061] The dry paste is crushed to obtain a Chinese medicine composition.

[0062] The yields of the first dry paste, the second dry paste and the third dry paste were measured, and the measuring method was as follows:

[0063] The first dry paste, the second dry paste and the third dry paste were respectively made up to 300 mL, 25 mL of the fixed volume dry paste solution was respectively taken and placed in an evaporating dish that had been dried to a constant weight, evaporated to dryness in a water bath, dried at 105°C for 6 h, taken out and placed in a desiccator to cool for 0.5 h, quickly weighed, and the dry paste yield was calculated according to the following formula. The results are shown in Table 1.

[0064] Dry paste yield (%) = (W×V) / (25×W1)×100%

[0065] Wherein, W represents the weight of dry paste, in g; W1 represents the total weight of raw material components, in g; V represents the fixed volume, in mL.

[0066] Table 1

[0067] Decoction times Dry paste yield (%) Proportion (%) first 15.18 63.84 Second time 6.59 27.71 The third time 2.01 8.45 Three times sum 23.78 100

[0068] As shown in Table 1, the dry extract yield obtained by the third decoction accounts for 8.45% of the total dry extract yield, indicating that the second decoction has been basically extracted completely. Therefore, the water extraction process of the second decoction is preferred.

[0069] Example 2

[0070] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0071] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and boil twice, add 14 times the amount of water for the first time and boil for 2.0 h to obtain the first decoction; add 12 times the amount of water for the second time and boil for 1.0 h to obtain the second decoction;

[0072] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0073] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0074] Example 3

[0075] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0076] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and boil twice, add 12 times the amount of water for the first time and boil for 2.0 h to obtain the first decoction; add 10 times the amount of water for the second time and boil for 1.0 h to obtain the second decoction;

[0077] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0078] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0079] Example 4

[0080] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0081] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 10 times the amount of water for the first time and decoct for 2.0 h to obtain the first decoction; add 8 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0082] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0083] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0084] The dry cream yield was calculated for the dry cream prepared in Examples 2 to 4. The dry cream was diluted to 800 mL, 25 ml of the diluted dry cream solution was taken and placed in an evaporating dish that had been dried to a constant weight, evaporated to dryness in a water bath, dried at 105°C for 6 h, taken out and cooled in a desiccator for 0.5 h, quickly weighed, and the dry cream yield was calculated according to the following formula. The results are shown in Table 2.

[0085] Table 2

[0086] Example Water addition amount (times) Dry paste yield (%) Example 2 14、12 21.43 Example 3 12、10 20.18 Example 4 10、8 19.55

[0087] As can be seen from Table 2, the dry paste yields of each water addition amount are not much different. Since the Chinese medicine composition of the present application contains more whole herb flavors, based on economic energy saving and to ensure complete extraction, it is preferred to add 12 times the amount of water for the first time and 10 times the amount of water for the second time.

[0088] Example 5

[0089] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0090] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 2.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 2.0 h to obtain the second decoction;

[0091] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0092] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0093] Example 6

[0094] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0095] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 2.0 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.5 h to obtain the second decoction;

[0096] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0097] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0098] Example 7

[0099] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0100] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0101] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 55° C. to 60° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 7 hours;

[0102] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0103] The dry cream yield was calculated for the dry cream prepared in Examples 5 to 7. The dry cream was fixed to 800 mL, 25 ml of the fixed volume of dry cream solution was taken, placed in an evaporating dish that had been dried to a constant weight, evaporated to dryness in a water bath, dried at 105°C for 6 h, taken out and placed in a desiccator to cool for 0.5 h, quickly weighed, and the dry cream yield was calculated according to the following formula. The results are shown in Table 3.

[0104] Table 3

[0105] Example Decoction time (h) Dry paste yield (%) Example 5 2.5、2.0 20.96 Example 6 2.0、1.5 20.05 Example 7 1.5、1.0 19.60

[0106] As can be seen from Table 3, the dry paste yields of Examples 5 to 7 are not much different. Based on the consideration of saving time and energy, it is preferred to add water and boil twice, with 12 times the amount of water added for the first time and boiling for 1.5 hours; and 10 times the amount of water added for the second time and boiling for 1.0 hour.

[0107] Example 8

[0108] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0109] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0110] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 60° C. to 65° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 5 hours;

[0111] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0112] Example 9

[0113] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0114] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0115] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.25 at 60° C., wherein the concentration temperature was 65° C. to 70° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 5 hours;

[0116] The thick paste is dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa to obtain a dry paste; the dry paste is crushed to obtain a traditional Chinese medicine composition.

[0117] The Chinese medicine compositions prepared in Examples 7 to 9 were observed to see whether bubbles were generated during the concentration process. The results are shown in Table 4.

[0118] Table 4

[0119] Example Concentration temperature (℃) Vacuum degree(MPa) Concentration time (h) Foaming Example 7 55~60 -0.08~-0.06 7 Not easy to foam Example 8 60~65 -0.08~-0.06 5 Not easy to foam Example 9 65~70 -0.08~-0.06 3 Easier to foam

[0120] Example Concentration temperature (°C) Vacuum degree (MPa) Concentration time (h) Foaming condition Example 7 55~60 -0.08~-0.067 Not easy to foam Example 8 60~65 -0.08~-0.065 Not easy to foam Example 9 65~70 -0.08~-0.063 Easier to foam.

[0121] As can be seen from Table 4, the concentration conditions within the above range can improve the quality of the Chinese medicine composition. Therefore, the concentration conditions are preferably: temperature 60°C to 65°C, vacuum degree -0.08MPa to -0.06MPa, and concentration to a relative density of about 1.20 to 1.25 (60°C).

[0122] Example 10

[0123] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0124] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0125] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.20 to .25 at 60° C., wherein the concentration temperature was 60° C. to 65° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 5 hours;

[0126] The thick paste was dried at a temperature of 50°C to 60°C and a vacuum degree of -0.08MPa to -0.06MPa for 11 hours to obtain a dry paste;

[0127] The dry paste is crushed to obtain a Chinese medicine composition.

[0128] Embodiment 11

[0129] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0130] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0131] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.20 to .25 at 60° C., wherein the concentration temperature was 60° C. to 65° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 5 hours;

[0132] The thick paste was dried at a temperature of 60°C to 70°C and a vacuum degree of -0.08MPa to -0.06MPa for 7 hours to obtain a dry paste;

[0133] The dry paste is crushed to obtain a Chinese medicine composition.

[0134] Example 12

[0135] This embodiment provides a Chinese medicine composition, comprising the following steps:

[0136] Weigh a total of 70 g of raw material components: 5 g of Codonopsis pilosula, 7.5 g of Astragalus, 5 g of Ligustrum lucidum, 5 g of Ganoderma lucidum, 5 g of Curcuma zedoaria, 7.5 g of Ranunculaceae, 5 g of Fritillaria thunbergii, 7.5 g of Scutellaria barbata, 7.5 g of Stinking Paeonia suffruticosa, 7.5 g of Dry Houttuynia cordata, 7.5 g of Hedyotis diffusa, add water and decoct twice, add 12 times the amount of water for the first time and decoct for 1.5 h to obtain the first decoction; add 10 times the amount of water for the second time and decoct for 1.0 h to obtain the second decoction;

[0137] The first decoction and the second decoction were filtered through a 200-mesh filter respectively, and the filtered decoctions were combined to obtain a filtrate; the filtrate was concentrated to a thick paste with a relative density of 1.20 to .25 at 60° C., wherein the concentration temperature was 60° C. to 65° C., the concentration vacuum was -0.08 MPa to -0.06 MPa, and the concentration time was 5 hours;

[0138] The thick paste was dried at a temperature of 70°C to 80°C and a vacuum degree of -0.08MPa to -0.06MPa for 4.5 hours to obtain a dry paste;

[0139] The dry paste is crushed to obtain a Chinese medicine composition.

[0140] Whether bubbles occur during the drying process of the traditional Chinese medicine compositions prepared in Examples 10 to 12 is used as an inspection index, and appropriate drying conditions are preferably selected.

[0141] Table 5

[0142] Example Drying temperature(℃) Drying time (h) Vacuum degree(MPa) Bubble situation Example 10 50~60 11 -0.08~-0.06 No foaming Embodiment 11 60~70 7 -0.08~-0.06 No foaming Example 12 70~80 4.5 -0.08~-0.06 There is foaming

[0143] As shown in Table 5, the dry pastes obtained in Examples 10 to 12 are relatively loose, but the drying time of Example 12 is relatively short and there is bubbling, which is because the high temperature easily destroys the effective ingredients in the dry paste. Therefore, the drying conditions are a temperature of 60°C to 70°C and a vacuum degree of -0.08 to -0.06 MPa.

[0144] Amplification experiment

[0145] A batch of scale-up experiments are carried out below to verify the feasibility of the preparation method of the Chinese medicine composition of the present application.

[0146] Table 6

[0147]

[0148] It can be seen from Table 6 that the indicators examined in the scale-up experiment all meet the requirements, and the dry paste yield is not much different from that of Examples 1 to 12, indicating that the process is stable and feasible.

[0149] Embodiment 13

[0150] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0151] Weigh 70 g of the Chinese medicine composition and 84 g of lactose, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0152] Embodiment 14

[0153] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0154] Weigh 70 g of the Chinese medicine composition and 84 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0155] Embodiment 15

[0156] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0157] Weigh 70 g of the Chinese medicine composition and 84 g of maltodextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0158] The preparation process of Examples 13 to 15 was tested, with whether the soft material was sticky, whether the granulation blocked the screen, whether the drying was agglomerated, the granulation condition, and the mouthfeel as the evaluation indicators, and the type of diluent was preferred. The results are shown in Table 7.

[0159] Table 7

[0160]

[0161] As shown in Table 7, dextrin does not block the screen during the granulation process, is easy to granulate after drying, has uniform particles, good solubility, and is cheap and has good moisture resistance. Therefore, dextrin is selected.

[0162] Example 16

[0163] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0164] Weigh 50 g of the Chinese medicine composition and 50 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0165] Embodiment 17

[0166] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0167] Weigh 50 g of the Chinese medicine composition and 70 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0168] Embodiment 18

[0169] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0170] Weigh 50 g of the Chinese medicine composition and 90 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0171] Embodiment 19

[0172] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0173] Weigh 50 g of the Chinese medicine composition and 75 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0174] Embodiment 20

[0175] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0176] Weigh 50 g of the Chinese medicine composition and 80 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0177] Embodiment 21

[0178] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0179] Weigh 50 g of the Chinese medicine composition and 85 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0180] Embodiment 22

[0181] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0182] Weigh 50 g of the Chinese medicine composition and 90 g of dextrin, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0183] The preparation process of Examples 16 to 22 was tested, with whether the soft material was sticky, whether the granulation blocked the screen, whether the drying was agglomerated, the granulation condition, and the taste as the evaluation indicators. The amount of dextrin was optimized, and the results are shown in Tables 8 and 9.

[0184] Table 8

[0185]

[0186] As shown in Table 8, from the perspective of the granulation process, as the amount of dextrin increases, the granulation process is better. When the ratio of the Chinese medicine composition to dextrin is 1:1.4-1.8, the granulation process is acceptable. From the perspective of granule yield, as the amount of auxiliary dextrin increases, the granule yield does not change much. When the ratio of the Chinese medicine composition to dextrin is 1:1.4-1.8, the granule yield tends to be stable.

[0187] It can be seen from Table 8 that, based on the granulation process and granule yield, when the ratio of the Chinese medicine composition to dextrin is 1:1.5-1.7, all the investigated indicators are good.

[0188] Embodiment 23

[0189] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0190] Weigh 100 g of mixed powder (traditional Chinese medicine composition and dextrin) and 0.3 g of stevioside, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0191] Embodiment 24

[0192] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0193] Weigh 100 g of mixed powder (traditional Chinese medicine composition and dextrin) and 0.5 g of stevioside, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0194] Embodiment 25

[0195] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0196] Weigh 100 g of mixed powder (traditional Chinese medicine composition and dextrin) and 0.7 g of stevioside, use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0197] The Chinese medicine preparations prepared in Examples 23 to 25 were investigated, and the taste was used as the investigation index to optimize the appropriate amount of flavor correctives. The results are shown in Table 9.

[0198] Table 9

[0199] Example Mixed powder(g) Stevia(g) Taste Embodiment 23 100 0.3 Bitter taste, average taste Embodiment 24 100 0.5 Slightly sweet, good taste Embodiment 25 100 0.7 Slightly sweet and bitter, average taste

[0200] Example Mixed powder (g) Stevia (g) Taste Example 23 1000.3 Taste is bitter, taste is average Example 24 1000.5 Taste is slightly sweet, taste is good Example 25 1000.7 Taste is slightly sweet and bitter, taste is average.

[0201] As can be seen from Table 9, taking taste as the evaluation index, Example 24 has a suitable taste, so the amount of stevia is 0.5%.

[0202] Embodiment 26

[0203] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0204] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 85% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0205] Embodiment 27

[0206] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0207] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 90% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0208] Embodiment 28

[0209] This embodiment provides a method for preparing a traditional Chinese medicine preparation, comprising the following steps:.

[0210] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0211] The Chinese medicine preparations prepared in Examples 26 to 28 were investigated, with the granulation condition as the investigation index, and the appropriate wetting agent concentration was selected. The results are shown in Table 10.

[0212] Table 10

[0213]

[0214] As shown in Table 10, when the ethanol concentration is 90%, the granule yield is the highest, the granules are easy to granulate, and the granules have uniform color. Therefore, 90% ethanol is selected as the wetting agent.

[0215] Embodiment 29

[0216] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0217] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 85% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0218] Embodiment 30

[0219] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0220] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 90% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0221] Embodiment 31

[0222] This embodiment provides a method for preparing a Chinese medicine preparation, comprising the following steps:

[0223] Weigh 100 g of mixed powder (traditional Chinese medicine composition, dextrin and stevioside), use 95% ethanol to make a soft material, use a 14-mesh sieve to granulate, dry at 60° C., and use a 12-mesh sieve to granulate.

[0224] The Chinese medicine preparations prepared in Examples 29 to 31 were investigated, and the granulation conditions were used as the investigation indicators to optimize the appropriate amount of wetting agent. The results are shown in Table 11.

[0225] Table 11

[0226]

[0227] It can be seen from Table 11 that when the dosage of 90% ethanol is 35 mL, all the indicators are good in terms of granulation process, granule yield and granule qualified rate. Therefore, 90% ethanol is selected as the wetting agent with a dosage of 35%.

[0228] Animal experiments

[0229] A nude mouse lung cancer transplant tumor model was established at the animal experimental level.

[0230] SPF BALB / c-nu nude mice, male, 4-6 weeks old, weighing 18-20 g, were purchased from Hunan Slake Experimental Animal Co., Ltd.

[0231] Human lung cancer cell line A549 was purchased from the Cell Bank of the Chinese Academy of Sciences with catalog number TCHu150.

[0232] Take A549 cells in the logarithmic growth phase and adjust the cell concentration to about 4×107 / mL. Use a microsyringe to subcutaneously inject 100 μL of A549 cell suspension into the middle and posterior part of the left armpit of nude mice. The mice were raised in an SPF animal room. 14 days after cell inoculation, small lumps were observed in the armpits of nude mice injected with cell suspension.

[0233] like Figure 1 As shown, pathological sections ( Figure 1 C) in the figure shows large and deformed nuclei, dark staining, and nuclear division phase. The cancer tissue is arranged in clusters and grows in a diffuse and infiltrative manner, which is confirmed to be tumor tissue and indicates tumor formation.

[0234] The experimental groups were divided into model group, chemotherapy group, and Chinese medicine preparation plus chemotherapy group, and the weight changes and relative tumor volume changes of mice in each group were statistically analyzed. The expression of α-SMA was detected by immunohistochemistry.

[0235] like Figure 1 In A, B and D, the chemotherapy group and the Chinese medicine combined chemotherapy group were able to shrink the tumor, the weight of the mice in the chemotherapy group decreased significantly, and the Chinese medicine combined chemotherapy group was able to stabilize the weight, and the difference was statistically significant. The chemotherapy group and the Chinese medicine combined chemotherapy group were able to reduce the expression of α-SMA, a marker of epithelial-mesenchymal transition in tumor tissue ( Figure 1E), the difference was statistically significant.

[0236] Cell experiments

[0237] like Figure 2 As shown in the results, Chinese herbal preparations can promote cell apoptosis, inhibit the EMT process by inhibiting the PI3K / p-Akt pathway of A549 cells, and downregulate the expression of key angiogenesis receptors VEGFR and matrix metalloproteinase MMP9, thereby playing an anti-lung cancer invasion and metastasis role. The experimental results were statistically significant (P < 0.05 or P < 0.01).

[0238] In summary, both cell experiments and animal experiments can show that the Chinese medicine preparation of the present application has the effect of inhibiting tumor cell proliferation and promoting apoptosis. The Chinese medicine composition can inhibit lung cancer cell proliferation and promote apoptosis, inhibit EMT process by inhibiting the PI3K / p-Akt pathway of A549 cells, downregulate the expression of angiogenic receptor VEGFR and matrix metalloproteinase MMP9, and play an anti-lung cancer invasion and metastasis effect ( Figure 3 ).

[0239] Clinical Trials

[0240] A total of 298 elderly patients with stage III and IV non-small cell lung cancer with deficiency of both qi and yin and internal stasis of toxins were selected as clinical research subjects. They were randomly divided into the treatment group, namely the Chinese medicine preparation plus chemotherapy group, and the control group chemotherapy group (149 cases in each group) according to the order of visit time. The research method of stratified randomization, parallel control, and multicenter observation was adopted. The subjects' clinical symptoms, KPS scores, disease progression time, median survival time, annual survival rate, tumor size, safety and other indicators were observed using unified and standardized diagnosis and efficacy judgment criteria. 4 weeks was one cycle, and two cycles were observed continuously. The efficacy and toxicity were evaluated after 2 cycles. Both groups strictly followed the treatment plan of each group. Antiemetic drugs and colony cell stimulating factors were routinely used during chemotherapy, but other anti-tumor drugs and treatment measures that affect immune function were strictly prohibited during treatment. All cases were followed up after the end of treatment. Chinese medicine could continue to be taken during the follow-up period. Follow-up was until the patient died or the follow-up deadline.

[0241] (1) TCM syndrome (clinical symptoms)

[0242] Refer to the "Guidelines for Clinical Research on New Chinese Medicines for the Treatment of Primary Bronchogenic Lung Cancer" and judge according to the changes in clinical symptom scores before and after treatment (0, 1, 2, and 3 points are given according to the severity of the symptoms, including none, mild, moderate, and severe). A decrease of 70% or more in the score after treatment compared with the score before treatment is considered significant improvement; a decrease of 30% or more in the score after treatment compared with the score before treatment, but less than 70% is considered partial improvement; a decrease of less than 30% in the score after treatment compared with the score before treatment, or no change in the score before and after treatment, or an increase in the score after treatment compared with the score before treatment, is considered no improvement.

[0243] Effective rate = (markedly effective + effective) / (markedly effective + effective + ineffective) × 100%.

[0244] The comparison of clinical symptom improvement after treatment between the two groups is shown in Table 12: Among the 149 cases in the treatment group, 38 cases were significantly improved, 87 cases were partially improved, 24 cases were not improved, and the total effective rate was 83.89%; among the 149 cases in the control group, 20 cases were significantly improved, 74 cases were partially improved, 55 cases were not improved, and the total effective rate was 63.08%. After statistical processing, the difference between the two groups was statistically significant (P < 0.05), indicating that the treatment group was superior to the control group in improving clinical symptoms.

[0245] Table 12

[0246] Group Number of cases Significant improvement Partial Improvement No improvement Total effective rate (%) Treatment Group 149 38 87 24 83.89 Control group 149 20 74 55 63.08

[0247] (2) Quality of life

[0248] The evaluation was based on the KPS behavioral status scoring standard. That is, an increase of 10 points or more after treatment compared with before treatment was considered an improvement; a decrease of 10 points or more was considered a decrease; and an increase or decrease of less than 10 points was considered stable.

[0249] The improvement of the quality of life between the two groups after treatment is shown in Table 13: Among the 149 cases in the treatment group, the Karnofsky score improved in 58 cases, stabilized in 67 cases, and decreased in 24 cases; among the 149 cases in the control group, the Karnofsky score improved in 37 cases, stabilized in 50 cases, and decreased in 62 cases. The difference between the two groups was statistically significant (P < 0.05), indicating that the improvement of the Karnofsky score in the treatment group was better than that in the control group.

[0250] Table 13

[0251] Group Number of cases improve Stablize reduce Effectiveness (%) Treatment Group 149 58 67 24 83.89 Control group 149 37 50 62 58.39

[0252] (3) Tumor efficacy

[0253] According to the RECIST solid tumor efficacy evaluation criteria, the efficacy is divided into CR (complete remission), PR (partial remission), SD (stable lesion), and PD (progressive lesion). The effective rate (RR) is CR+PR, and the stable rate is CR+PR+SD.

[0254] As shown in Table 14, the total effective rate (CR+PR) of the two groups was 25.5% and 21.47%, respectively, with no significant difference (P>0.05); the tumor stability rate (CR+PR+NC) was 85.23% and 66.44%, respectively, with significant difference (P<0.05). This shows that TCM combined with chemotherapy has more clinical advantages in stabilizing tumors than chemotherapy alone.

[0255] Table 14

[0256] Group Number of cases Complete remission Partial remission Stablize Lesion progression Effectiveness (%) Stability rate (%) Treatment Group 149 3 35 92 29 25.5% 85.23 Control group 149 3 29 67 50 21.47 66.44

[0257] (4)Weight

[0258] An increase of ≥1.5kg in body weight after treatment compared with before treatment is considered an increase, a decrease of ≥1.5kg after treatment compared with before treatment is considered a decrease, and no change in body weight or an increase or decrease of less than 1.5kg is considered stable.

[0259] After treatment in both groups, as shown in Table 15, in the treatment group, 37 of the 149 cases had an increase in weight, 88 of the cases were stable, and 24 of the cases were decreased; in the control group, 19 of the 149 cases had an increase in weight, 72 of the cases were stable, and 58 of the cases were decreased. The difference between the two groups was statistically significant (P < 0.05), and the weight improvement in the treatment group was better than that in the control group.

[0260] Table 15

[0261] Group Number of cases improve Stablize decline Treatment Group 149 37 88 24 Control group 149 19 72 58

[0262] (5) Toxic side effects

[0263] According to the WHO acute and subacute toxic reactions and grading standards of anticancer drugs, the evaluation is divided into 0 to 4 degrees.

[0264] The clinical side effects and laboratory abnormalities that occurred during this study were mainly caused by chemotherapy drugs, among which digestive tract reactions (nausea, vomiting and diarrhea), peripheral blood and abnormal liver function were the main ones. After the second cycle of chemotherapy in the control group, the incidence of nausea, vomiting, leukopenia and abnormal liver function of grade 1-2 was 27.62%, 42.57% and 14.55%, respectively, and the incidence of grade 3-4 was 5.23%, 11.36% and 4.33%, respectively. In the treatment group, there were 7 cases of epigastric discomfort after taking Chinese medicine, but there were no obvious changes in peripheral blood, liver and kidney function and electrocardiogram related to treatment.

[0265] (6) Time to disease progression (TTP) and annual survival rate

[0266] This study started to follow up every 3 months after the end of the observation and medication. The time to disease progression (TTP) was 6.56 months in the treatment group and 4.25 months in the control group, with a statistically significant difference between the two groups (P < 0.05); the 6-month overall survival rate of the two groups was 93% in the treatment group and 87% in the control group, with no statistically significant difference (P > 0.05); the 12- and 18-month overall survival rates of the two groups were 64% and 47% in the treatment group, respectively; and 30% and 22% in the control group, respectively, with statistically significant differences (P < 0.05). Clinical studies have verified that Chinese medicine preparations are safe and effective in treating elderly non-small cell lung cancer. It suggests that Chinese medicine has good efficacy and distinctive characteristics in improving patients' clinical symptoms, reducing toxic and side effects caused by chemotherapy, improving quality of life, regulating function, improving physical fitness, and prolonging survival.

[0267] Finally, it should be noted that the above experimental examples are only used to illustrate the technical solutions of the present application, rather than to limit them. Although the present application has been described in detail with reference to the aforementioned experimental examples, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned experimental examples, or replace some or all of the technical features therein with equivalents. These modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the experimental examples of the present application.

Claims

1. A granule of a Chinese medicine composition is used in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The Chinese medicine composition comprises the following raw material components by weight: 5 to 30 parts of Codonopsis pilosula; 7.5 to 45 parts of Astragalus membranaceus; 5 to 30 parts of Ganoderma lucidum; 7.5 to 45 parts of Cat's Claw; 7.5 to 45 parts of Houttuynia cordata; 5 to 30 parts of Ligustrum lucidum; 5 to 30 parts of Curcuma zedoaria; 5 to 30 parts of Fritillaria thunbergii; 7.5 to 45 parts of Scutellaria barbata; 7.5 to 45 parts of Clerodendrum foetida; 7.5 to 45 parts of Hedyotis diffusa.

2. The granules of the Chinese medicine composition according to claim 1 are used in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The Chinese medicine composition comprises the following raw material components by weight: 5 to 25 parts of Codonopsis pilosula; 7.5 to 40 parts of Astragalus membranaceus; 5 to 25 parts of Ganoderma lucidum; 7.5 to 35 parts of Cat's Claw; 7.5 to 40 parts of Houttuynia cordata; 5 to 20 parts of Ligustrum lucidum; 5 to 20 parts of Curcuma zedoaria; 5 to 26 parts of Fritillaria thunbergii; 7.5 to 38 parts of Scutellaria barbata; 7.5 to 40 parts of Clerodendrum foetida; and 7.5 to 37 parts of Hedyotis diffusa.

3. The granules of the Chinese medicine composition according to claim 1 are used in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The preparation method of the granules of the Chinese medicine composition comprises the following steps: Weighing the raw material components of the traditional Chinese medicine composition according to proportion, extracting the raw material components, and obtaining a filtrate after filtering; concentrating the filtrate to obtain a thick paste; Drying the thick paste to obtain a dry paste; The dry paste is crushed to obtain granules of the traditional Chinese medicine composition.

4. The granules of the Chinese medicine composition according to claim 1 are used in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The raw material components of the traditional Chinese medicine composition are weighed according to a proportion, and the raw material components are extracted, and a filtrate is obtained after filtering, comprising the following steps: Weighing raw material components of the traditional Chinese medicine composition according to proportion, adding water to the raw material components to perform decoction twice, and obtaining a first decoction liquid and a second decoction liquid respectively; The first decoction and the second decoction are filtered respectively, and then the filtered medicinal liquids are combined to obtain the filtrate; wherein the weight ratio of the amount of water added for each decoction to the total weight of the raw material components is 10 to 12:1, and the time for each decoction is 60 minutes to 90 minutes.

5. The granules of the Chinese medicine composition according to claim 1 are used in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The filtrate is concentrated to obtain a thick paste, comprising the following steps: Concentrating the filtrate to a thick paste having a relative density of 1.20 to 1.25 at 60° C.; Wherein, the concentration temperature is 60°C to 65°C, and the concentration vacuum degree is -0.08MPa to -0.06MPa.

6. Use of the granules of the Chinese medicine composition according to claim 1 in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The step of drying the thick paste to obtain a dry paste comprises the following steps: The thick paste is dried at a temperature of 60° C. to 70° C. and a vacuum degree of -0.08 MPa to -0.06 MPa to obtain a dry paste.

7. Use of the granules of the Chinese medicine composition according to claim 1 in the preparation of a drug for inhibiting the PI3K / p-Akt pathway, characterized in that: The granules of the Chinese medicine composition further include the auxiliary materials; The auxiliary materials include diluents, sweeteners and wetting agents; The mass ratio of the Chinese medicine composition to the diluent is 1:(1.4-1.8), and the mass ratio of the Chinese medicine composition to the sweetener is The amount ratio is 1: (0.003-0.007), and the amount of the wetting agent is 30 mL-40 mL per 100 g of the traditional Chinese medicine composition; The diluent is selected from dextrin; The sweetener is selected from stevia; The wetting agent is selected from ethanol.

Citation Information

Patent Citations

  • Stagnation-removing decoction oral liquid and preparation method thereof

    CN104415290A